Segmed
+0%
est. 2Y upside i
Real-World Data for Health Innovation
Rank
#2025
Sector
Healthcare Technology
Est. Liquidity
~4Y
Data Quality
Data: LowEquity upside is highly uncertain due to missing valuation and growth data.
Last updated: July 3, 2026
Exit multiple expands to 10x on IPO window and category leadership; projected revenue $12.2M yields exit value $122M, 2.3x entry before dilution.
Multiple converges to 6x, in line with public comps; exit value $73.2M, 1.4x entry before dilution, but 20% dilution reduces net upside.
Multiple compresses to 3x due to big tech competition; exit value $36.6M below entry, with dilution and preference overhang further eroding common value.
Preference Stack Risk
severeFunding Intensity
3900%Total funding $20.3M implies a 39% preference overhang on the implied $52M valuation, meaning common stock faces substantial pre-money risk.
Dilution Risk
highWith no disclosed cash runway and moderate capital intensity, a further raise within 12-18 months is likely, diluting common by ~20%.
Secondary Liquidity
noneNo secondary market transactions have been identified; employee equity is illiquid until a liquidity event.
Questions to Ask at the Interview
Strategic questions based on Segmed's data — designed to show you've done your homework.
- 1
“How does Segmed differentiate its platform from Truveta and big tech healthcare cloud offerings?”
- 2
“What is the revenue mix between SaaS subscriptions and data licensing, and how does that affect margin scalability?”
- 3
“What is the current option pool size and strike price relative to the latest round valuation?”
Community
Valuation Sentiment
Our model estimates +0% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.